MK-8521
Biological
Merck Sharp & Dohme Corporation
Total Payments
$1.0M
Transactions
421
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $38,461 | 61 | 0 |
| 2017 | $996,896 | 360 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.0M | 421 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects with Type 2 Diabetes Mellitus | Merck Sharp & Dohme Corporation | $1.0M | 0 |
Top Doctors Receiving Payments for MK-8521
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chattanooga, TN | $1.0M | 421 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $1.0M
- Total Doctors 0
- Transactions 421
About MK-8521
MK-8521 is a biological associated with $1.0M in payments to 0 healthcare providers, recorded across 421 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2018. In 2018, $38,461 was paid across 61 transactions to 0 doctors.
The most common payment nature for MK-8521 is "Unspecified" ($1.0M, 100.0% of total).
MK-8521 is associated with 1 research study, including "A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects with Type 2 Diabetes Mellitus" ($1.0M).